Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer.

ABSTRACT:

Background

Single-agent chemotherapy with or without bevacizumab (Bev) is a standard therapy for platinum-resistant ovarian cancer (PR-OC). However, there is a lack of literature on chemotherapy agent selection in heterogenous PR-OC. Therefore, we aimed to clarify the heterogeneous treatment effects of each chemotherapy agent.

Methods

Patients who underwent single-drug chemotherapy agents or Bev combination therapy for PR-OC between January 2009 and June 2022 were included in this study. We assessed the impact of each chemotherapy agent on the time to treatment failure (TTF) according to histological type, platinum-free interval (PFI), and Bev usage.

Results

A total of 158 patients received 343 different chemotherapy regimens. In patients with clear cell carcinoma/muc

SUBMITTER: Nara K 

PROVIDER: S-EPMC10468735 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature